anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The system described herein enables clinicians and researchers to use aggregated genetic and phenotypic data from clinical trials and medical records to make the safest, most effective treatment decisions for each patient. This involves (i) the creation of a standardized ontology for genetic, phenotypic, clinical, pharmacokinetic, pharmacodynamic and other data sets, (ii) the creation of a translation engine to integrate heterogeneous data sets into a database using the standardized ontology, and (iii) the development of statistical methods to perform data validation and outcome prediction with the integrated data. The system is designed to interface with patient electronic medical records (EMRs) in hospitals and laboratories to extract a particular patient's relevant data. The system may also be used in the context of generating phenotypic predictions and enhanced medical laboratory reports for treating clinicians. The system may also be used in the context of leveraging the huge amount of data created in medical and pharmaceutical clinical trials. The ontology and validation rules are designed to be flexible so as to accommodate a disparate set of clients. The system is also designed to be flexible so that it can change to accommodate scientific progress and remain optimally configured.
Pain is a private experience observable through various verbal and non-verbal behavioural manifestations, each of which may relate to different pain-related functions. Despite the importance of understanding the cerebral mechanisms underlying those manifestations, there is currently limited knowledge of the neural correlates of the facial expression of pain. In this functional magnetic resonance imaging (fMRI) study, noxious heat stimulation was applied in healthy volunteers and we tested if previously published brain signatures of pain were sensitive to pain expression. We then applied a multivariate pattern analysis to the fMRI data to predict the facial expression of pain. Results revealed the inability of previously developed pain neurosignatures to predict the facial expression of pain. We thus propose a facial expression of pain signature (FEPS) conveying distinctive information about the brain response to nociceptive stimulations with minimal or no overlap with other pain-relevant brain signatures associated with nociception, pain ratings, thermal pain aversiveness, or pain valuation. The FEPS may provide a distinctive functional characterization of the distributed cerebral response to nociceptive pain associated with the socio-communicative role of non-verbal pain expression. This underscores the complexity of pain phenomenology by reinforcing the view that neurosignatures conceived as biomarkers must be interpreted in relation to the specific pain manifestation(s) predicted and their underlying function(s). Future studies should explore other pain-relevant manifestations and assess the specificity of the FEPS against simulated pain expressions and other types of aversive or emotional states.
RETEVMO can cause concentration-dependent QT interval prolongation [see Clinical Pharmacology (12.2)]. An increase in QTcF interval to >500 ms was measured in 7% of patients and an increase in the QTcF interval of at least 60 ms over baseline was measured in 20% of patients [see Adverse Reactions (6.1)]. RETEVMO has not been studied in patients with clinically significant active cardiovascular disease or recent myocardial infarction.

Monitor patients who are at significant risk of developing QTc prolongation, including patients with known long QT syndromes, clinically significant bradyarrhythmias, and severe or uncontrolled heart failure. Assess QT interval, electrolytes and TSH at baseline and periodically during treatment, adjusting frequency based upon risk factors including diarrhea. Correct hypokalemia, hypomagnesemia and hypocalcemia prior to initiating RETEVMO and during treatment.

Monitor the QT interval more frequently when RETEVMO is concomitantly administered with strong and moderate CYP3A inhibitors or drugs known to prolong QTc interval. Withhold and reduce the dose or permanently discontinue RETEVMO based on the severity [see Dosage and Administration (2.5)].
PURPOSE: To obtain treated powder excellent in water repellency, good in spreadability on the skin, favorable in touch feeling in its use, and excellent in the prevention of color darkening due to sebum, etc., during using e.g. a foundation, and to obtain a cosmetic containing the powder. CONSTITUTION: The treated powder is obtained by surface treatment of synthetic mica, e.g. synthetic fluorophlogopite of formula KMg3 (AlSi3 O10 )F2 , with an N-mono long chain aliphatic acyl basic amino acid (and/or salt thereof) (pref. N-lauroyllysine or a salt thereof in terms of handleability). The amount of the surface treating agent is 0.1-10wt.% based on the synthetic mica. The treatment may be through either dry or wet process; the water repelling effect is higher for wet process. The powder is formulated at 1-50wt.% based on the cosmetic. The effect of the powder formulation is the most significant for powder cosmetics or solid powder cosmetics, and for powder-rich foundations, etc., even in the case of oily or emulsified cosmetics.
The drug substance in NEXOBRID, anacaulase-bcdb, is a mixture of proteolytic enzymes extracted from the stems of pineapple plants (Ananas comosus [L.] Merr.) that has been sterile filtered and lyophilized. The drug substance, anacaulase-bcdb, is composed mainly (80% to 95% w/w) of the proteins: stem bromelain, ananain, jacalin-like lectin, bromelain inhibitors, and phytocystatin inhibitor; and saccharides, as both free monosaccharides and the N-linked glycan of stem bromelain, and small molecule metabolites. The drug substance includes inactive buffer components containing acetic acid, ammonium sulfate, and Water for Injection. Each gram of lyophilized powder contains 0.97 grams of anacaulase-bcdb. 

NEXOBRID (anacaulase-bcdb) for topical gel is a botanical drug product supplied as a sterile, preservative-free, lyophilized powder in a single-dose glass vial that must be mixed in a gel vehicle supplied in a single-dose glass jar prior to application. Mixture of either 2 grams of lyophilized powder (containing 1.94 grams of anacaulase-bcdb) or 5 grams of lyophilized powder (containing 4.85 grams of anacaulase-bcdb) in 20 grams or 50 grams of gel vehicle, respectively, provides an 8.8% w/w, yellowish white to light brown opaque gel for topical use. The pH of the topical gel mixture is approximately 6.2 to 6.7.

The co-packaged 20 gram or 50 gram jar of the sterile, preservative-free gel vehicle contains carbomer 980, dibasic sodium phosphate, sodium hydroxide, and Water for Injection.
PROBLEM TO BE SOLVED: To obtain the subject maintaining agent useful as an additive to culture media for culturing nerve cells or their tissue or as a medicine for treating or preventing Alzheimer's disease, Parkinson's disease, etc., accompanying neurodegeneration by adding a life protein originating from Drosophila melanogaster. SOLUTION: This maintaining agent contains a life protein originating from Drosophila melanogaster. The life protein can be obtained from the early chrysalis of the Drosophila melanogaster. The life protein can be obtained as a protein having a mol.wt. of 77,000 by treating the homogenate supernatant of the early chrysalis of Drosophila melanogaster by anion exchange column chromatography such as DEAE-Sephacel, Con-A column chromatography and gel filtration. The obtained life protein may be compounded with a pharmaceutical carrier, etc., (for example, a binder, a vehicle) to prepare a proper preparation. The life protein may be used as a food additive used in health foods/drinks.
NEW MATERIAL:A compound shown by the formula I (-A- is double bond, or epoxy) shown by the formula I . EXAMPLE:A 8,9-14,15-diepoxy derivative of milbemycin D. USE:An acaricide. An insecticide. Showing improved activity against acarids living in fruits, vegetables, etc., outer parasites such as flies, fleas, lice, etc., sanitary noxious insects such as cookroaches, etc. Having improved vermicidal activity as a vermicide for domestic animals and man. PROCESS:A compound shown by the formula II is reacted with an organic peroxide (e.g., metachloroperbenzoic acid, performic acid, etc.) or hydrogen peroxide in a solvent such as chloroform, benzene, etc. at -20-50 deg.C for 1-10hr to give a compound shown by the formula I . The amount of the organic peroxide or hydrogen peroxide is 2.5-3 equivalents when A is double bond, and 5-6 equivalents when A is epoxy. The reaction is carried out optionally in the presence of optical active tartaric acid, to give a corresponding optical active epoxy derivative.
Participants with mild AD dementia who tested amyloid positive were observed for up to 36 months. No therapeutic investigational drug intended to treat AD was administered.
CBIT is an 8 session treatment protocol held over 10 weeks. In CBIT, core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child. Each core component is briefly described below. HRT/CBIT involves three components, awareness training, competing response training, and social support training (Woods, Twohig, Roloff, \& Flessner, 2003). For this condition, CBIT will be combined with adjunctive computerized response inhibition training, which will be delivered over the first 4 weeks of the CBIT treatment.
Surgical site infection (SSI) following lumbar disc herniation (LDH) surgery leads to prolonged hospital stays, increased costs and reoperations. Therefore, we aim to develop and validate a nomogram to predict the risk of SSI following LDH surgery, thereby helping spine surgeons design personalized prevention strategies and promote early recovery. Data from 647 patients with SSI who underwent LDH surgery at the First Affiliated Hospital of Air Force Medical University (AFMU) from 2020 to 2023 were collected. Ultimately, 241 patients with SSI were selected based on inclusion and exclusion criteria. Patients were randomly divided into training and validation sets with a ratio of 7:3. LASSO regression, univariate, and multivariate logistic regression were utilized to identify target variables and establish the prediction model, which was subsequently validated. Six factors-Age, Body Mass Index (BMI), Postoperative Suction Drainage (PSD), Gelatin Sponge (GS), None-Preoperative Antibiotic (NPTA), and Thrombin Time (TT)-were selected to construct the nomogram model. In the training set, the area under the curve (AUC) for the nomogram was 0.818 (95% CI 0.779-0.857). In the validation set, the AUC was 0.782 (95% CI 0.717-0.846). Calibration curves for both sets showed satisfactory agreement between predicted and actual SSI probabilities. Decision curve analysis indicated that the nomogram is clinically useful with a threshold range of 1-90%. The Clinical Impact Curve (CIC) demonstrated an acceptable cost-benefit ratio. The developed nomogram model effectively predicts the risk of SSI following LDH surgery, enabling spine surgeons to formulate more professional and rational clinical prevention strategies.
Distilled water as placebo with a bitter flavor added (to mimic the bitter metallic taste of SDF) was painted onto all exposed tooth root surfaces using a small disposable brush. This procedure will be repeated after 12 and 24 months.In addition, instructions on oral hygiene (OHI) tailored to the individual's condition was given, and a tube of toothpaste containing 1,000 ppm fluoride (the most popular type of adult toothpaste in the Hong Kong market) was provided. The OHI and provision of toothpaste will be repeated at 6-month intervals.
PURPOSE:To obtain a bathing agent composition, containing an alkali metallic salt of silicic acid and/or metasilicic acid and an organic acid under specific conditions, having skin beautifying effects due to an improvement in flexibility, elasticity and wrinkles of the skin after bathing and excellent in preservation stability and solubility. CONSTITUTION:This bathing agent composition contains an alkali metallic salt of silicic acid and/or metasilicic acid coated with a water-soluble polymer which is a solid at normal temperatures and a solid water-soluble organic acid (e.g. citric acid or tartaric acid). The coating treatment is carried out by using a method for mixing and stirring the powdery alkali metallic salt of silicic acid and/or metasilicic acid (e.g. sodium salt) with the solid water-soluble polymer (e.g. polyethylene glycol) at 1:(0.5-1.5) weight ratio and mechanically coating the alkali metallic salt with the water-soluble polymer, treating the water-soluble polymer liquefied by heating and then cooling and granulating the treated alkali metallic salt, etc. The bathing agent composition is completely soluble in hot water without floating foreign materials and flocculating mutual particles during the preservation.
The invention is concerned with epitopes derived from human papilloma virus, and peptides having a size of about 22-45 amino acid residues comprising minimal T cell epitopes. The invention further provides clinically relevant approaches for immunizing subjects against (Myco)bacterially and/or virally infected cells or tumor cells, and in particular against HPV. The invention demonstrates that peptide sequences of 22-35 amino acid residues in length can induce both peptide-specific CD8+ cytolytic cells and CD4+ T-helper cells. Moreover, the invention demonstrates that vaccination with 22-35 residue long peptides results in a more vigorous CD8+ cytolytic T-cell response than vaccination with peptides of the exact minimal CTL epitope length.; The invention further demonstrates that the intrinsic capacity of certain minimal CTL epitopes which instead of activating cytolytic effector cells tolerize these cytolytic cells, can be overcome by use of these 22-35 amino acid long peptides. The invention further provides clinically relevant approaches for vaccination and/or treatment of subjects against HPV. The invention also provides methods and uses suited to treat subjects suffering from progressive lesions and/or cervical cancer.
The invention relates to the technical field of biological medicines, and particularly discloses a composition with an anesthetic effect and application thereof in preparing anesthetic products. The invention firstly provides application of tetrahydropalmatine in preparing an anesthetic product. The invention also provides an application of the solasodine in preparing an anesthetic product. The invention also provides an application of the dihydrochelerythrine in preparing anesthetic products. The invention also provides a composition which comprises any two or more of tetrahydropalmatine, solasonine and dihydrochelerythrine. Because the tetrahydroellipticine, the solasonine and the dihydro chelerythrine and the composition thereof have anesthetic effect; therefore, the active ingredient of the compound has important application value in preparing anesthetic.
<P>PROBLEM TO BE SOLVED: To provide an edible fat-and-oil composition having antiobese effect, thermally stable enough to withstand a heating process in producing processed food and heat cooking such as (deep)-frying, and to provide beverages and feed each using the same.  <P>SOLUTION: The edible fat-and-oil composition contains 4-campestenone. The beverages using either kind of the above composition containing 4-campestenone as active ingredient and having antiobese effect are provided. Specifically, the beverages include beverages for body-slimming use, antidiabetic foods, foods for preventing arteriosclerosis, neutral fat-reducing foods or foods for hypotensive use. The feed using the above composition is also provided.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Biomarker guided corticosteroid use. Initiation of corticosteroid will be recommended based on the an individual treatment rule (ITR) and subsequent dosing of corticosteroid will be recommended based on daily CRP values till CRP \<50 mg/L.
Small molecule therapeutics can concentrate in distinct intracellular environments, some bounded by membranes, and others that may be formed by membrane-less biomolecular condensates. The chemical environments within biomolecular condensates have been proposed to differ from those outside these bodies, but the internal chemical environments of diverse condensates have yet to be explored. Here we use small molecule probes to demonstrate that condensates formed in vitro with the scaffold proteins of different biomolecular condensates harbor distinct chemical solvating properties. The chemical rules that govern selective partitioning in condensates, which we term condensate chemical grammar, can be ascertained by deep learning, allowing efficient prediction of the partitioning behavior of small molecules. The rules learned from in vitro condensates were adequate to predict the partitioning of small molecules into nucleolar condensates in living cells. Different biomolecular condensates harbor distinct chemical environments, that the chemical grammar of condensates can be ascertained by machine learning.
The present invention relates to emulsion with perfluoro organic compounds (PFOCs) with gas transportation performance for intravascular medication. The present invention comprises perfluorocarbon which can be fast eliminated by organism and perfluoro trialkylamine which can be slowly eliminated by the organism, the present invention further comprises a small amount of at least three kinds of PFOC mixing materials, structures and physicochemical properties of the PFOC mixing materials are similar to those of major ingredients, and the materials form a series of PFOC with gradual change properties. The emulsion also comprises a small amount of H-perfluoro paraffin hydrocarbon filling materials, so the composition can form uniform and stable non-cluster perfluorocarbon phases in emulsion particles. The PFOC emulsion is stabilized by polyethylene glycol oxide and polypropylene oxide copolymers. The composition preparation improves the stability of the emulsion when the emulsion is stored and enters into blood streams; the viscosity of the PFOC emulsion is reduced; the high dynamic oxygen capacity of the preparation is ensured; the tissue oxygen transmission is improved. During the preparation of the emulsion, stabilizing agents are heated at a temperature higher than 75 DEG C; all ingredients are saturated by carbon dioxide; homogenization is carried out under the condition of carbon dioxide introduction; thus, the peroxide generation is reduced, and the reactogenicity is reduced. The PFOC emulsion can be used for treating gas-lipid embolia, acra occlusion blood vessel injury and lipophilic poison toxicosis, and can also be used for preventing various kinds of toxicity injury caused by xenobiotic.
Hyperuricemia may occur or frank gout may be precipitated in certain patients receiving thiazide therapy. Thiazides have been shown to increase the urinary excretion of magnesium; this may result in hypomagnesemia. Thiazides may decrease urinary calcium excretion. Thiazides may cause intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Marked hypercalcemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function. In diabetic patients, dosage adjustment of insulin or oral hypoglycemic agents may be required. Hyperglycemia may occur with thiazide diuretics. Thus, latent diabetes mellitus may become manifest during thiazide therapy. The antihypertensive effects of hydrochlorothiazide may be enhanced in postsympathectomy patients.
A programmable nuclease for use in a method of durable treating a microbial infection in a subject. The infection is caused by microbes of a first species or strain. The nuclease is programmed to cut a target site within the genome of the microbes, thereby durably killing or reducing growth or proliferation of the microbes. The method comprises reducing infection 100 fold for at least 60 minutes after exposing the subject to the nuclease. The subject is on an immunosuppressant medication. The method can comprise use of RNA that complexes with the nuclease to target the nuclease to the target site. The infection can be vaginosis, meningitis, pneumonia, a urinary tract infection, cystitis, nephritis, gastroenteritis, a skin infection, impetigo, erysipelas, cellulitis, septicaemia or sepsis. The subject can be a cancer patient. The nuclease can be a Cas nuclease, a meganuclease, a TALEN, or zinc finger nuclease. Further aspects of the invention are viruses, phages, phagemids, compositions, vectors, viriophages, plasmids or transposons comprising a copy of the nucleic acid encoding the nuclease. A further aspect is a CRISPR/Cas system comprising the nuclease and a guide RNA. The microbes can be E. coli (e.g., EHEC), C. difficile, Klebsiella, or Pseudomonas bacteria.
Compositions for coating pharmaceutical tablets, pellets and pills comprise a solution of polyvinyl pyrrolidone and a solid polyethylene glycol in a pharmaceutically acceptable solvent. Suitable glycols have a molecular weight of 1000 to 10,000, preferably of 2000 to 6000, and may comprise 1:1 to 9:1, or better, 2:1 to 6:1 with relation to the weight of polyvinyl pyrrolidone. Solvents used may be acetone, chloroform, carbon tetrachloride, pet. ether, benzene, toluene, xylene, methyl ethyl ketone, trichloroethylene, ethylene-dichloride, trichloroethane with methylene chloride, or methyl-, ethyl-, or isopropyl alcohol, or mixtures of these. The dissolved solids may constitute 3 to 18% of the solution. The coating is applied by covering the tablets with the solution and evaporating off the solvent.ALSO:A method for stabilising the surface of wax-fat coated sustained release pharmaceutical tablets, pellets, or pills comprises covering the said forms with a solution of polyethylene glycol and polyvinylpyrrolidone in a volatile pharmaceutically acceptable solvent, and allowing them to dry.  The process is suitably performed in a coating pan, or using air suspension or fluid bed methods.  Polyethylene glycols used are solids, of M.W. of 1,000 to 10,000, preferably from 2,000 to 6,000, and are used in ratio 2 : 1 to 6 : 1 of the polyvinylpyrrolilone the finishing coat is suitably 0.25 to 5% by weight of the tablet, pill, or pellet.  The purpose of the coat is to preserve the original gloss and lustre of the wax coat on storage.  Examples are given of such coatings applied to sustained release forms containing as active ingredients 1) chlorpromazine hydrochloride and 2) chlorprophenpyridamine maleate.
Participants will undergo one trial visit where they will ingest an oral glucose load diluted in solution (oral glucose tolerance test) and blood samples will be measured over the following 2-hours. The buffy coat layer from the baseline sample will be obtained to extract DNA.
Hair dyeing agents based on oxidn. dyes contain 5,6-diamino-4-oxo-pyrimidine derivs. of formula: in which R1-R4 = H, 1-4C alkyl, 1-4C hydroxyalkyl, phenyl, substd. phenyl or aralkyl gp., or R1 and R2 together with the N atom form a heterocyclic 5- or 6-ring which opt. contains a further N or O atom; X = O or S, and their (in)organic salts, as developing agents together with couplers normally used in oxidn. hair dyes. (I) are toxicologically and dermatologically more acceptable than prior art couplers such as m-phenylenediamine derivs., phenols, naphthols, resorcinol derivs. and pyrazolones, and gives the desired colour tones in sufficient intensity with good affinity to human hair.